

NIDDK 2006 Urolithiasis Symposium  
March 9-10, 2006  
Wyndham Baltimore Inner Harbor

**Agenda**

**Thursday, March 9**

7:55 a.m. - 8:00 a.m.	<b>Welcome</b>	<i>Gary Curhan</i>
8:00 a.m. - 10:00 a.m.	<b>Clinical Management Oral Session</b>	
8:00 a.m. - 9:00 a.m.	Medical Management of Stone Disease <b>Moderator: David S. Goldfarb</b> <ul style="list-style-type: none"><li>• Future of trials in urolithiasis</li><li>• New medications for stone prevention</li><li>• Physiologic issues in the clinical management of calcium phosphate stones</li><li>• Management of stones in the pediatric population</li><li>• Long-term stone prevention: adherence and adverse effects of medications</li><li>• Pharmacogenomics and the prevention of stone recurrence</li></ul>	<i>Leroy Nyberg Jr. and John Kusek John Asplin Mitch Halperin Craig Langman David Goldfarb Carla Monico</i>
9:00 a.m. - 10:00 a.m.	Surgical Management of Stone Disease <b>Moderator: Martin Resnick</b> <ul style="list-style-type: none"><li>• Shockwave lithotripsy</li><li>• Percutaneous nephrolithotomy</li><li>• Ureterscopy</li><li>• Laparoscopic approaches for renal and ureteral calculi</li></ul>	<i>James Lingeman Steven Nakada John Denstedt Stuart Wolf</i>
10:00 a.m. - 10:10 a.m.	Comment Period for Clinical Management Session	
10:10 a.m. - 10:30 a.m.	<b>Break</b>	
10:30 a.m. - 11:45 a.m.	<b>Imaging</b> <b>Moderator: Dawn Milliner</b> <ul style="list-style-type: none"><li>• Preferred imaging modalities for stones</li><li>• The future of stone imaging/New modalities to reduce radiation exposure</li><li>• Determination of stone composition and fragility by imaging</li></ul>	<i>Bruce McClennan Cynthia McCollough James Williams</i>
11:45 a.m. - 11:55 a.m.	Comment Period for Imaging Oral Session	
12:00 noon –1:00 p.m.	<b>Lunch</b>	

1:00 p.m. - 2:00 p.m.	<b>Critical Steps for Stone Formation</b> <b>Moderator: Michael D. Ward</b> <ul style="list-style-type: none"> <li>• Earliest phases of stone formation <i>Fred Coe</i></li> <li>• Biomineralization of Uric Acid <i>Jennifer Swift</i></li> <li>• Mechanisms of action of relevant urinary inhibitors <i>Jeff A. Wesson</i></li> <li>• Cellular response to oxalate challenges <i>Julie Jonassen</i></li> </ul>
2:00 p.m. - 2:10 p.m.	Comment Period for Stone Structure/Crystal Attachment Oral Session
2:10 p.m. - 3:40 p.m.	<b>*Breakout Meetings</b> <ul style="list-style-type: none"> <li>• Clinical management</li> <li>• Imaging</li> <li>• Critical Steps for Stone Formation</li> </ul>
	<b>Moderator</b> <i>Martin Resnick and David S. Goldfarb</i> <i>Dawn Milliner</i> <i>Michael Ward</i>
3:40 p.m. - 4:00 p.m.	<b>Break</b>
4:00 pm. - 5:15 p.m.	<b>Pathophysiology</b> <b>Moderator: Elaine Worcester</b> <ul style="list-style-type: none"> <li>• Mechanisms of hypercalciuria <i>Fred Coe</i></li> <li>• Uric acid and stone disease <i>Khashayar Sakhaee</i></li> <li>• Obesity, bariatric surgery, and stone disease <i>Elaine Worcester</i></li> <li>• Oxalate absorption and renal handling <i>David Mount</i></li> <li>• Importance of citrate handling in stone disease <i>Patricia Preisig</i></li> </ul>
5:15 p.m. - 5:25 p.m.	Comment Period for Pathophysiology
5:30 p.m.	<b>Adjourn</b>
<b><u>Friday, March 10</u></b>	
7:30 a.m. - 8:30 a.m.	<b>Animal models</b> <b>Moderator: John Lieske</b> <ul style="list-style-type: none"> <li>• Models of hyperoxaluria: is any one preferred? <i>Neil Mandel</i></li> <li>• What can models of hypercalciuria teach us about human nephrolithiasis? <i>David Bushinsky</i></li> <li>• Other models of intrarenal crystal deposition <i>Jay Tischfield</i></li> <li>• Newer genetic models of calcium stone disease <i>Xue-Ru Wu</i></li> </ul>
8:30 a.m. - 8:40 a.m.	Comment period
8:40 a.m. - 9:55 a.m.	<b>Genetics/Genomics/Proteomics Oral Session</b> <b>Moderator: Orson Moe</b> <ul style="list-style-type: none"> <li>• Can transcriptional profiling help with understanding kidney stones? <i>Matthias Kretzler</i></li> <li>• Should NIDDK have a core facility and database for nephrolithiasis research? <i>Erwin Bottinger</i></li> <li>• The potential role of urinary proteomics in nephrolithiasis <i>John Arthur</i></li> <li>• Application of proteomics in renal tissue from patients with nephrolithiasis <i>TBD</i></li> </ul>
9:55 a.m. - 10:05 a.m.	Comment period for Genetics/Genomics/Proteomics Oral Session

10:05 a.m. - 11:50 a.m.	<b>*Breakout Meetings</b> <ul style="list-style-type: none"> <li>• Pathophysiology</li> <li>• Animal Models</li> <li>• Genetics/genomics/proteomics</li> </ul>	<b>Moderator</b> <i>Elaine Worcester</i> <i>John Lieske</i> <i>Orson Moe</i>
11:50 a.m. -12:50 p.m.	Presentation of Major Recommendations by Each Breakout Group	
1: 00 p.m.	<b>Adjourn</b>	

\*The breakout sessions will not have posters or talks. The goal is to have a discussion about the issues that will be raised during the talks and by the breakout moderators. A written document will be prepared from each breakout session describing the recommendations for future research in the area.